Laser Ablation of Papillary Thyroid Microcarcinoma

Pilot Study to Evaluate the Safety and Efficacy of Percutaneous Laser Ablation of Thyroid Papillary Microcarcinoma

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04623801

Enrollment

Registered

2020-11-10

Start date

2020-10-19

Completion date

2026-10-01

Last updated

2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Papillary Thyroid Microcarcinoma, Thyroid, Thyroid Cancer

Keywords

PTMC, Papillary Thyroid Microcarcinoma, Thyroid Cancer, Percutaneous Laser Ablation, PLA, 19-438, Memorial Sloan Kettering Cancer Center

Brief summary

The purpose of this study is to explore whether percutaneous laser ablation (PLA) is a safe and effective alternative to removing papillary thyroid microcarcinoma (PTMC) with surgery.

Interventions

PROCEDUREPercutaneous Laser Ablation (PLA)

Percutaneous Laser Ablation / PLA will be carried out in a single session by advancing one 21-gauge spinal needle into the target lesions under real time US guidance.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age ≥ 18 years * Papillary thyroid cancer documented by * (a) Bethesda VI cytology, * (b) Bethesda III, IV, V, or VI cytology AND BRAF V600E mutation, or * (c) Bethesda V cytology AND high risk ultrasonographic features documented by either the ATA high suspicion or TIRADS 5 nodule characteristics To ensure the majority of cases will be eligible based on criteria (a) or (b), we will enroll ≤ 2 patients based on criteria (c). * Maximum diameter ≤ 13 mm * Declined active surveillance * The thyroid lesion must be primarily solid with ≤ 25% cystic compent * No US evidence of extrathyroidal extension through the thyroid capsule * No imaging evidence of lymph node metastasis * Preserved contralateral vocal cord function prior to PLA

Exclusion criteria

* Thyroid cancer that is non papillary thyroid cancer (PTC) * Thyroid lesion with \> 25% cystic component * Lesion with US evidence of extrathyroidal extension through the thyroid capsule * Clinical or ultrasonographic evidence of lymph node metastasis * Pregnancy

Design outcomes

Primary

Measure	Time frame	Description
Number of participants with complete thermal ablation	6 months	Complete thermal ablation of the targeted PTMC (T1aN0M0) as determined by histological examination of thyroid tissue obtained by either thyroid lobectomy or total thyroidectomy 6 months after PLA.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORR. Michael Tuttle, MD

Memorial Sloan Kettering Cancer Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 11, 2026